Pilatus Biosciences, a biotechnology company developing immunometabolic therapies for cancer, today announced a preclinical publication in Cancer Discovery detailing the mechanism and therapeutic ...

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or ...

The tumor microenvironment (TME) is a complex and dynamic network consisting of tumor cells, immune cells, stromal cells, ...

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...

Detailed price information for Medicenna Therapeutics Corp (MDNA-T) from The Globe and Mail including charting and trades.

Positive results of PARP inhibitor and CAR T-cell treatments highlight advances in research for neuroblastoma.

LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland ...

Aulostm Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic, today presented positive results from its ...